Raltegravir 	Raltegravir 	 NNP	B-NP
:  	:  	 :	O
molecular  	molecular  	 JJ	B-NP
basis  	basis  	 NN	I-NP
of  	of  	 IN	O
its  	its  	 PRP$	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action  	action  	 NN	B-NP
Integration  	Integration  	 NNS	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
HIV-1  	HIV-1  	 NNP	I-NP
viral  	viral  	 JJ	I-NP
DNA  	DNA  	 NN	I-NP
generated  	generated  	 VBD	O
by  	by  	 IN	O
reverse  	reverse  	 JJ	B-NP
transcription  	transcription  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
RNA  	RNA  	 NNP	I-NP
genome  	genome  	 NN	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
host  	host  	 NN	B-NP
cell  	cell  	 NN	I-NP
chromosomes  	chromosomes  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
key  	key  	 JJ	B-NP
step  	step  	 NN	I-NP
of  	of  	 IN	I-NP
viral  	viral  	 JJ	I-NP
replication 	replication 	 NN	I-NP
,  	,  	 ,	O
catalyzed  	catalyzed  	 VBG	O
by  	by  	 IN	O
the  	the  	 DT	O
viral  	viral  	 JJ	B-NP
integrase 	integrase 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
October  	October  	 NNP	O
2007 	2007 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
first  	first  	 JJ	O
integrase  	integrase  	 JJ	B-NP
inhibitor 	inhibitor 	 NN	I-NP
,  	,  	 ,	O
raltegravir 	raltegravir 	 NN	B-NP
,  	,  	 ,	O
was  	was  	 VBD	O
approved  	approved  	 VBN	O
for  	for  	 IN	O
clinical  	clinical  	 JJ	B-NP
use  	use  	 NN	I-NP
under  	under  	 IN	O
the  	the  	 DT	O
name  	name  	 NN	O
of  	of  	 IN	O
Isentress  	Isentress  	 NNP	B-NP
superset 	superset 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
various  	various  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
that  	that  	 WDT	O
have  	have  	 VBP	O
evaluated  	evaluated  	 VBN	B-NP
raltegravir  	raltegravir  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
very  	very  	 RB	O
encouraging  	encouraging  	 VBG	O
with  	with  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
immunological  	immunological  	 NN	B-NP
and  	and  	 CC	O
virological  	virological  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
and  	and  	 CC	O
tolerance 	tolerance 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
as  	as  	 RB	O
observed  	observed  	 VBN	O
for  	for  	 IN	O
other  	other  	 JJ	O
anti-retrovirals 	anti-retrovirals 	 NN	B-NP
,  	,  	 ,	O
specific  	specific  	 JJ	O
resistance  	resistance  	 NN	B-NP
mutations  	mutations  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
identified  	identified  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
failing  	failing  	 VBG	O
to  	to  	 TO	O
respond  	respond  	 VB	O
to  	to  	 TO	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
raltegravir 	raltegravir 	 NN	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
knowledge  	knowledge  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
integrase  	integrase  	 JJ	B-NP
structural  	structural  	 JJ	I-NP
biology  	biology  	 NN	I-NP
remains  	remains  	 VBZ	O
fragmentary 	fragmentary 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
structures  	structures  	 NNS	O
and  	and  	 CC	O
modeling  	modeling  	 JJ	O
data  	data  	 NNS	O
available  	available  	 JJ	O
might  	might  	 MD	O
provide  	provide  	 VB	O
relevant  	relevant  	 JJ	O
clues  	clues  	 NNS	O
on  	on  	 IN	O
the  	the  	 DT	O
origin  	origin  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
emergence  	emergence  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
resistance  	resistance  	 NN	B-NP
mutations 	mutations 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
describe  	describe  	 VBP	O
the  	the  	 DT	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action  	action  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
drug  	drug  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
main  	main  	 JJ	O
data  	data  	 NNS	O
relating  	relating  	 VBG	O
to  	to  	 TO	O
its  	its  	 PRP$	O
use  	use  	 NN	O
in  	in  	 IN	O
vivo 	vivo 	 NN	B-NP
,  	,  	 ,	O
together  	together  	 RB	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
structural  	structural  	 JJ	B-NP
data  	data  	 NNS	I-NP
important  	important  	 JJ	O
to  	to  	 TO	O
our  	our  	 PRP$	O
understanding  	understanding  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
origin  	origin  	 NN	O
of  	of  	 IN	O
viral  	viral  	 JJ	B-NP
resistance 	resistance 	 NN	I-NP
.  	.  	 .	O
